IDO1 and neoplasm: Based on IHC expression of immune co-inhibitory molecules in our cohort, tumor cells of SCLC were found to be poor immuno-expresser of PD-L1 and IDO1, while CTLA-4 immunolabelling was seen in a fair number of cases.